In the past, we analyzed the role of Galectin-3 and MCP-1, and we saw how elevated levels of these biomarkers were associated with an increase in cardiovascular events [4] as well as these biomarkers improving the ability of the LIPID clinical scale to predict the prognosis of patients with stable coronary artery disease [25]. Here, CCL2 is linked to coronary artery disorder.